Global Chronic Fatigue Syndrome Market, By Type (Immune Enhancer & Antivirals, Sleep Enhancing, CNS Stimulants, Others), End-User (Hospitals, Clinics, Research Institutes) - Industry Trends and Forecast to 2030.
Chronic Fatigue Syndrome Market Analysis and Size
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME). CFS is a complex and debilitating medical condition characterized by extreme fatigue, cognitive impairments, pain, and other symptoms that significantly impact a person's daily life.
Data Bridge Market Research analyses that the chronic fatigue syndrome market was valued at USD 47.2 million in 2022 and is expected to reach the value of USD 68.2 million by the year 2030, at a CAGR of 4.2% during the forecast period. This indicates that the market value. "Immune Enhancer & Antivirals" dominates the type segment of the chronic fatigue syndrome market owing to the increasing prevalence of chronic fatigue syndrome globally. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chronic Fatigue Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Immune Enhancer & Antivirals, Sleep Enhancing, CNS Stimulants, Others), End-User (Hospitals, Clinics, Research Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
|
|
Market Players Covered
|
Cortene Inc. (U.S.), Hemispherx Biopharma Inc. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Mitsubishi Tanabe Pharma Corporation (Japan), Tonix Pharmaceuticals Holding Corp. (U.S.), Solve ME/CFS Initiative (U.S.), Johnson & Johnson (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), Sanofi (France), AstraZeneca plc (U.K.), , Eli Lilly and Company (U.S.), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), Gilead Sciences, Inc. (U.S.) among others.
|
|
Market Opportunities
|
|
Market Definition
Chronic fatigue syndrome is also known as myalgic encephalomyelitis, a chronic disorder associated with long-term fatigue and tiredness in patients. Any particular condition cannot define these symptoms. Even with continued rest, the patient's condition is not improved, this disorder is not very well known, and no solidified information is available for its cause.
Chronic Fatigue Syndrome Market Dynamics
Drivers
- Increasing Prevalence of Chronic Fatigue Syndrome Globally
The rising number of individuals diagnosed with chronic fatigue syndrome. This in turn, has carved the way for the market's growth. The increasing need for therapies that alleviate symptoms and enhance the quality of life for chronic fatigue syndrome patients fuels market growth.
- Advancements in Medical Technology
Technological advancements in medical devices and regenerative medicine have increased the demand for innovative chronic fatigue syndrome. With improved biocompatibility, strength, and durability are being developed to enhance patient outcomes.
Opportunities
- Government Funding and Initiatives
The government initiatives, schemes, or funding that support and promotes the innovation and development of the chronic fatigue syndrome market provide growth opportunities for the market players in the forecast period of 2023 to 2030. Additionally, development of biomarkers and diagnostic tools increasing research and development activities, penetration rate, market expansion in developing countries, nanotechnology and advanced materials methods globally, and increasing per capita expenditure on health care will further expand the market's growth rate in the future.
Restraints/ Challenges
High Development Costs
The development and commercialization of chronic fatigue syndrome involve significant research and development costs. The high cost of testing, clinical trials, and obtaining regulatory approvals can restrain smaller market players.
Lack of Standardized Diagnostic Criteria for CFS
Leading to variations in diagnosis and treatment approaches: Inconsistent diagnostic criteria can result in differences in diagnosing CFS, affecting the development of uniform treatment strategies. Also, limited understanding and awareness of CFS among healthcare providers in developing economies, stigma and skepticism surrounding CFS, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.
This chronic fatigue syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chronic fatigue syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2022, The Center for Disease Control (CDC) in the U.S. estimated that 836,000 to 2.5 million Americans suffer from CFS. However, the majority of them are undiagnosed
Global Chronic Fatigue Syndrome Market Scope
The chronic fatigue syndrome treatment market is segmented on the basis of type and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Immune Enhancer & Antivirals
- Sleep Enhancing
- CNS Stimulants
- Others
End User
- Hospitals
- Clinics
- Research Institutes
Chronic Fatigue Syndrome Market Regional Analysis/Insights
The chronic fatigue syndrome market is analysed and market size insights and trends are provided by country, type, and end user, as referenced above.
The countries covered in the Chronic Fatigue Syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the chronic fatigue syndrome market due to changing lifestyles and increasing healthcare expenditure rise in the availability of funds for research, huge patient population, increasing healthcare expenditures, well-developed healthcare sector, and government support for research & development in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the huge patient population, chronic fatigue syndrome market, and rise in the presence of huge opportunities in the market in this region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The chronic fatigue syndrome market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for chronic fatigue syndrome market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the chronic fatigue syndrome market. The data is available for historic period 2015-2020.
Competitive Landscape and Chronic Fatigue Syndrome Market Share Analysis
The chronic fatigue syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the chronic fatigue syndrome market are:
- Cortene Inc. (U.S.)
- Hemispherx Biopharma Inc. (U.S.)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Tonix Pharmaceuticals Holding Corp. (U.S.)
- Solve ME/CFS Initiative (U.S.)
- Johnson & Johnson (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Merck & Co., Inc. (U.S.)
- Sanofi (France)
- AstraZeneca plc (U.K.)
- Eli Lilly and Company (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Biogen Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Amgen Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
SKU-